

IN THE CLAIMS:

1-31. (Canceled)

32. (Currently Amended) A pharmaceutical composition for the treatment of female hormonal deficiencies ~~a mixture of estrogenic compounds, wherein said mixture consists~~ consisting essentially of:

a mixture of estrogenic compounds, wherein said mixture comprises salts of conjugated estrone, conjugated equilin, conjugated  $\Delta^{8,9}$ -dehydroestrone, conjugated 17 $\alpha$ -estradiol, conjugated 17 $\beta$ -dihydroequilin, conjugated 17 $\alpha$ -dihydroequilin, conjugated 17 $\beta$ -estradiol, conjugated equilenin, conjugated 17 $\alpha$ -dihydroequilenin, and conjugated 17 $\beta$ -dihydroequilenin; and

a therapeutically effective amount of a non-aromatizing androgenic compound, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing; and

a pharmaceutically acceptable carrier.

33. (Canceled)

34. (New) A pharmaceutical composition for the treatment of female hormonal deficiencies consisting essentially of:

a mixture of estrogenic compounds, wherein said mixture comprises salts of conjugated estrone, conjugated equilin, conjugated  $\Delta^{8,9}$ -dehydroestrone, conjugated 17 $\alpha$ -estradiol, conjugated 17 $\beta$ -dihydroequilin, conjugated 17 $\alpha$ -dihydroequilin, conjugated 17 $\beta$ -estradiol, conjugated equilenin, conjugated 17 $\alpha$ -dihydroequilenin, and conjugated 17 $\beta$ -dihydroequilenin;

a therapeutically effective amount of a non-aromatizing androgenic compound, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol,

pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing;

a therapeutically effective amount of a progestin compound; and  
a pharmaceutically acceptable carrier.

35. (New) A pharmaceutical composition for the treatment of female hormonal deficiencies consisting essentially of:

a mixture of estrogenic compounds, wherein said mixture comprises salts of conjugated estrone, conjugated equilin, conjugated  $\Delta^{8,9}$ -dehydroestrone, conjugated 17 $\alpha$ -estradiol, conjugated 17 $\beta$ -dihydroequilin, conjugated 17 $\alpha$ -dihydroequilin, conjugated 17 $\beta$ -estradiol, conjugated equilenin, conjugated 17 $\alpha$ -dihydroequilenin, and conjugated 17 $\beta$ -dihydroequilenin;

a therapeutically effective amount of a progestin compound; and  
a pharmaceutically acceptable carrier.